2020
DOI: 10.1038/s41419-020-03233-y View full text |Buy / Rent full text
|
|

Abstract: Sorafenib, a multikinase inhibitor, is considered as the only approved drug to cure the advanced hepatocellular carcinoma (HCC); however, the acquired chemoresistance caused by intratumoral hypoxia through sorafenib long term therapy induces sorafenib inefficacy. We demonstrated here that hypoxia significantly attenuated sensitivity of HCC cells to sorafenib treatment and reduced its proliferation. Autophagy was observed in sorafenib-treated HCC cells in hypoxia, and inhibition of autophagy by 3-MA eliminated … Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
0
35
0

Publication Types

Select...

Relationship

0
0

Authors

Journals